GO
Loading...

Roche Holding AG

More

  • What new GSK cancer deal shows about pharma market Monday, 2 Jun 2014 | 3:33 AM ET

    The announcement that GSK is planning to spend $350 million plus to get a slice of a U.K. biotech's cancer drugs has raised eyebrows.

  • BEIJING, May 29- Johnson& Johnson, Bausch& Lomb Inc and other major producers have been fined more than 19 million yuan for fixing prices in China's eye glass and contact lens market, China's top economic regulator said on Thursday. Swiss drugmaker Roche Holding AG had also been visited by a unit of China's anti-trust regulator.

  • Chinese city targets pharma firms in graft crackdown Tuesday, 27 May 2014 | 9:08 AM ET

    SHANGHAI, May 27- China's eastern city of Hangzhou is cracking down on graft in the healthcare sector, according to an internal memo from the local government, putting more pressure on global drugmakers operating in the country.

  • How AstraZeneca escaped Pfizer clutches...this time Tuesday, 27 May 2014 | 8:20 AM ET

    Could things have turned out differently? Yes, according to one source in the AstraZeneca camp who pointed to a flaw in Pfizer's strategy.

  • *China anti-trust watchdog visits Roche office. *China cracking down on wider pharma sector. SHANGHAI/ ZURICH, May 22- Swiss drugmaker Roche Holding AG said it had been visited by a unit of China's anti-trust regulator- a move that comes amid a widening crackdown on corruption and high prices in the country's pharmaceutical sector.

  • Drugmaker Roche says visited by authorities in China Thursday, 22 May 2014 | 3:04 AM ET

    SHANGHAI/ ZURICH, May 22- Swiss drugmaker Roche Holding AG said on Thursday it had been visited by a unit of China's anti-trust regulator, amid increasing scrutiny over business practices in the pharmaceutical sector in the country.

  • SHANGHAI, May 18- Chinese corruption charges against executives of British drugmaker GlaxoSmithKline Plc could be just the start of the pharmaceutical industry's problems in its biggest emerging drugs market, according to industry sources in China.

  • May 14- When the world's leading cancer doctors meet in Chicago next month, new treatments from Merck& Co, Bristol-Myers Squibb Co and Roche Holding AG that help the immune system fight disease are expected to capture much of the spotlight.

  • May 14- When the world's leading cancer doctors meet in Chicago next month, new treatments from Merck& Co, Bristol-Myers Squibb Co and Roche Holding AG that help the immune system fight disease are expected to capture much of the spotlight.

  • This year, at ASCO, all eyes are on pharma Wednesday, 14 May 2014 | 3:41 PM ET

    Some stocks moved after the bell after abstracts for the American Society of Clinical Oncology meeting dropped Wednesday.

  • LONDON, May 6- AstraZeneca Plc laid out its defence against Pfizer Inc's $106- billion takeover approach on Tuesday by predicting its sales would rise by three quarters over the next decade, although only after a short-term drop. "These are benefits that should fully accrue to AstraZeneca's shareholders."

  • LONDON, May 6- AstraZeneca Plc laid out its defence against Pfizer Inc's $106 billion takeover approach on Tuesday by predicting its revenues would rise 75 percent over the next decade, although only after a short-term drop. "These are benefits that should fully accrue to AstraZeneca's shareholders."

  • *India welcomes U.S. trade decision. NEW DELHI, May 1- India said on Thursday it would hold trade talks on intellectual property rights with the United States after its general election, buying time to address friction over drug patents until a new government is formed.

  • COLUMN-When the best offense is defensive stocks Wednesday, 23 Apr 2014 | 4:30 PM ET

    LONG BEACH, Calif., April 23- You've been on offense with your global stock portfolio for five years, running up the score in sectors like consumer discretionary and technology stocks that have outperformed the broad market. Jamie Doyle, co-manager of the Causeway Global Value Fund, is not ready to make a wholesale switch into defensive plays.

  • Why this biotech is rushing in as big pharma exits Wednesday, 16 Apr 2014 | 3:23 PM ET
    Barry Greene, Alnylam Pharmaceuticals

    This week the headline appeared to have some tough news for RNA companies, but Alnylam remains undeterred about the potential of its treatments.

  • Europe shares close lower; Ukraine concerns persist Tuesday, 15 Apr 2014 | 12:07 PM ET

    European shares closed lower on Tuesday, as Ukraine worries and fears about slowing demand in China weighed on stocks.

  • ZURICH, April 15- A strong uptake of new cancer medicines helped Roche to limit a decline in first-quarter sales and the Swiss company confirmed a forecast for higher earnings this year.

  • Roche looks to cancer drug to offset strong franc Tuesday, 15 Apr 2014 | 3:58 AM ET

    Swiss pharmaceuticals company Roche posted a rise in first-quarter sales but failed to meet market expectations as a strong Swiss franc hit results.

  • We are pleased with share price: Roche CEO     Tuesday, 15 Apr 2014 | 3:20 AM ET

    Severin Schwan, CEO of Roche, says he is "pleased" with the share price and results reported by the company.

  • *Q1 sales 11.496 bln Swiss francs vs 11.887 bln forecast. ZURICH, April 15- Adverse currency moves weighed on first-quarter sales at Roche Holding AG, which fell 1 percent, despite a healthy uptake of its new cancer medicines.